Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors

Summary

The aim was to evaluate the efficacy and safety of two recombinant factor VIIa (rFVIIa) dose regimens for treating haemarthroses in patients with congenital haemophilia A or B and inhibitors. This was a multi-centre, randomised, cross-over, double-blind trial. Patients were randomly allocated to treat a first joint bleeding episode with one 270 µg/kg rFVIIa dose followed by two doses of placebo at 3-hour intervals and a second joint bleed with three single doses of 90 µg/kg rFVIIa at 3-hour intervals, or vice versa. Efficacy was evaluated using a novel and robust treatment response-rating scale based on patient-assessment of pain and joint mobility. Outcome was rated at different timepoints, and an effective or ineffective treatment response was determined. Treatment “preference” was defined as effective treatment with one regimen and ineffective with the other. Patients with equally effective or ineffective treatments had no “preference”. Treatment was rated as effective for 65% of patients using the 270 µg/kg dose versus 70% for the 90 µg/kg ×3 regimen. An equal “preference” was noted for the two regimens (21% for each; p = 0.637); most patients (58%) had no “preference”. 37/42 bleeding episodes (88%) were successfully treated with rFVIIa; additional haemostatic medications were administered for five episodes. No safety issues were identified. Administration of rFVIIa as a single 270 µg/kg dose to treat haemarthroses in patients with haemophilia and inhibitors was at least as efficacious and safe as the 90 µg/kg ×3 regimen.

Keywords

Recombinant FVIIa - haemophilia - inhibitor - high-dose - home treatment

• References

• 1 Key NS, Aledort LM, Beardsley D. et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
• 2 Ingerslev J, Thykjaer H, Kudsk-Jensen O. et al. Home treatment with recombinant activated factor VII: results from one centre. Blood Coagul Fibrinolysis 1998; 09 Suppl: (Suppl. 01) S107-10.
• 3 Laurian Y, Goudemand J, Negrier C. et al. Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998; 09 Suppl: (Suppl. 01) S155-6.
• 4 Sumner WT, Monroe DM, Hoffman M. Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 1996; 81: 533-43.
• 5 Erhardtsen E, Nony P, Dechavanne M. et al. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998; 09: 741-8.
• 6 Schulman S, D’Oiron R, Martinowitz U. et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis 1998; 09: S97-101.
• 7 Schulman S, Bech-Jensen M, Varon D. et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996; 75: 432-6.
• 8 Shapiro AD, Gilchrist GS, Hoots WK. et al. Prospective, randomised trial of two doses of rFVIIa (Novo-Seven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
• 9 Villar A, Aronis S, Morfini M. et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352-9.
• 10 Kenet G, Lubetsky A, Luboshitz J. et al. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 01: 450-5.
• 11 Parameswaran R, Shapiro AD, Gill JC. et al. Dose effect and efficacy of recombinant factor VIIa (rFVIIa) in the treatment of hemophilia patients with inhibitors: analysis from the Hemophilia Research Society (HRS) Registry. Blood. 2002 100. Abstract.
• 12 Cooper HA, Jones CP, Campion E. et al. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 07: 517-22.
• 13 Abshire TC. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing. Semin Hematol 2004; 41 Suppl: (Suppl. 01) 3-7.
• 14 Kenet G, Lubetsky A, Luboshitz J. et al. High dose recombinant activated factor VII for treatment of patients with hemophilia and inhibitors. Haemophilia 2004; 10 Suppl: (Suppl. 03) 53-66.
• 15 Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol 1998; 63 (Suppl): 7-10.
• 16 Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999; 104: 22-6.
• 17 Key NS, Nelsestuen GL. Views on methods for monitoring recombinant factor VIIa in inhibitor patients. Semin Hematol 2004; 41 Suppl: (Suppl. 01) 51-4.
• 18 World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-6.
• 19 Gerotziafas GT, Chakroun T, Depasse F. et al. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 2004; 91: 977-85.
• 20 Lorand L. Sol Sherry Lecture in Thrombosis: research on clot stabilization provides clues for improving thrombolytic therapies. Arterioscler Thromb Vasc Biol 2000; 20: 2-9.
• 21 Rodriguez-Merchan EC. Haemophilic arthropathy in haemophilia patients with inhibitors: new perspectives. Haemophilia 2003; 09: 547-8.
• 22 Lusher JM, Eyster ME, Hilgartner MW. et al. Panel discussion on the treatment of patients with factor-VIII inhibitors. Prog Clin Biol Res 1984; 150: 323-35.